Bristol Myers braves failed Reblozyl phase 3, plans FDA talks for potential anemia expansion Fierce Pharma BMS’ Anemia Drug Reblozyl Flunks Phase III Myelofibrosis Trial BioSpace Bristol Myers Squibb’s Reblozyl fails Phase 3 in anemia; Sanofi, Blueprint deal closes Endpoints News Retail Chatter On BMY Doubles In 24 Hours With Drug Failing To Meet Primary Goal: Here’s What Investors Are Thinking Stocktwits Luspatercept Plus …
Read More »